studyId: syn56417025 studyName: A Phase 1-2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-Tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous initiative: Partnership fundingAgency: NTAP